Enfortumab vedotin-pembrolizumab shows durability advantage over chemotherapy at three-year follow-up in bladder cancer trial ...

JAMA's 2026 editorial exposes how "pragmatic trial" has been stretched beyond recognition, threatening regulatory credibility ...

AI deployment in clinical studies requires validation framework and governance structure to address compliance gaps and ...

FDA's September 2026 adcomm recruitment push signals shifts in protocol feedback loops that sponsor clinops and sites can't ...

CRScube and Mednet demonstrate integration-free EHR-to-EDC tool designed to reduce manual transcription errors and streamline clinical data capture.

Cemiplimab maintains disease-free survival benefit in high-risk CSCC with 68% risk reduction versus placebo in extended ...

Forward Therapeutics' FT2109 advances to Phase 2 after clearing Phase 1 with once-daily oral dosing and a supportive safety ...

Most sites undercharge on research-paid items because no one reconciles the sponsor budget against the charge master. Here is ...

Headlands Research Portland site marks 50 years of continuous Alzheimer's trials, contributing to every FDA-approved ...

A pilot RCT links psilocybin's 25 mg dose to reduced egocentric bias in alcohol use disorder, exposing a blind spot in how ...

First-in-human trial targets the amygdala with focused ultrasound in MDD, raising hard questions about biomarker selection, ...

Jon Himoff, Chief Product Officer of Image Analysis Group (IAG), on why purpose-built imaging platforms outperform assembled ...